HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES
    32.
    发明申请
    HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES 审中-公开
    脂质体内充电治疗药物的高效包扎

    公开(公告)号:US20120114831A1

    公开(公告)日:2012-05-10

    申请号:US13195692

    申请日:2011-08-01

    IPC分类号: B05D3/10

    摘要: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.

    摘要翻译: 提供了制备脂质 - 核酸组合物的方法。 根据该方法,将包含可质子化或不可质令排泄的脂质,例如氨基脂质和脂质如PEG-或聚酰胺低聚物修饰的脂质的脂质混合物与带电疗法的缓冲水溶液组合,例如 聚阴离子核酸,以产生其中治疗剂包封在脂质囊泡中的颗粒。 脂质颗粒上的表面电荷至少部分被中和,以提供治疗剂的表面中和的脂质包封的组合物。 该方法允许制备具有高比例的治疗剂与脂质并且包封效率超过50%的组合物。

    HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES
    33.
    发明申请
    HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES 有权
    脂质体内充电治疗药物的高效包扎

    公开(公告)号:US20080200417A1

    公开(公告)日:2008-08-21

    申请号:US12028696

    申请日:2008-02-08

    摘要: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.

    摘要翻译: 提供了制备脂质 - 核酸组合物的方法。 根据该方法,将包含可质子化或不可质令排泄的脂质,例如氨基脂质和脂质如PEG-或聚酰胺低聚物修饰的脂质的脂质混合物与带电疗法的缓冲水溶液组合,例如 聚阴离子核酸,以产生其中治疗剂包封在脂质囊泡中的颗粒。 脂质颗粒上的表面电荷至少部分被中和,以提供治疗剂的表面中和的脂质包封的组合物。 该方法允许制备具有高比例的治疗剂与脂质并且包封效率超过50%的组合物。

    Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
    34.
    发明授权
    Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias 失效
    脂质体组合物和使用脂质体组合物治疗脂肪血症的方法

    公开(公告)号:US06773719B2

    公开(公告)日:2004-08-10

    申请号:US09924222

    申请日:2001-08-07

    IPC分类号: A61K9127

    摘要: The present invention provides a liposomal composition for treating dislipidemias in human subjects, a method of using a liposomal composition, and devices and modes of operation of the devices and of the compositions, and kits related thereto. The invention provides for the reverse transport of cholesterol from peripheral tissues to the liver in a warm blood mammal while controlling plasma atherogenic lipoprotein concentrations, including LDL concentrations. A method described above and mode of operation of the devices includes the stop of administering an effective amount of a multiplicity of acceptors comprised of phospholipids substantially free of sterol. A method described above optionally includes the stop of periodically assaying atherogenic lipoprotein concentrations with an assay during the treatment period to assess atherogenic lipoprotein concentrations and obtain an atherogenic lipoprotein profile.

    摘要翻译: 本发明提供了一种用于治疗人受试者的脂质脂质的脂质体组合物,使用脂质体组合物的方法,以及装置和组合物的装置和操作模式,以及与其相关的试剂盒。 本发明提供了在温血哺乳动物中将外周组织向肝脏逆转运输,同时控制血浆致动脉粥样化脂蛋白浓度,包括LDL浓度。 上述方法和装置的操作模式包括停止施用有效量的由基本上不含固醇的磷脂组成的多个受体。 上述方法任选地包括在治疗期间通过测定来定期测定致动脉粥样化脂蛋白浓度,以评估致动脉粥样化脂蛋白浓度并获得致动脉粥样化脂蛋白分布。